Apyx Medical (NASDAQ:APYX) Stock Price Up 6.8%

Shares of Apyx Medical Corp (NASDAQ:APYX) rose 6.8% during mid-day trading on Tuesday . The company traded as high as $3.58 and last traded at $3.46, approximately 198,110 shares were traded during mid-day trading. An increase of 111% from the average daily volume of 93,700 shares. The stock had previously closed at $3.24.

APYX has been the subject of a number of recent analyst reports. ValuEngine raised shares of Apyx Medical from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, March 3rd. BidaskClub raised shares of Apyx Medical from a “sell” rating to a “hold” rating in a research report on Wednesday, February 12th. Piper Sandler reduced their price objective on shares of Apyx Medical from to in a research report on Tuesday, March 17th. Finally, Zacks Investment Research downgraded shares of Apyx Medical from a “buy” rating to a “hold” rating in a research report on Tuesday, January 14th. Two equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $8.55.

The stock’s 50-day simple moving average is $6.26 and its 200-day simple moving average is $7.14. The firm has a market capitalization of $110.71 million, a P/E ratio of -6.55 and a beta of 0.46. The company has a current ratio of 8.73, a quick ratio of 7.93 and a debt-to-equity ratio of 0.01.

Apyx Medical (NASDAQ:APYX) last released its earnings results on Monday, March 16th. The company reported ($0.16) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.19) by $0.03. Apyx Medical had a negative net margin of 66.19% and a negative return on equity of 23.33%. The firm had revenue of $8.38 million during the quarter. On average, equities research analysts expect that Apyx Medical Corp will post -1 EPS for the current year.

Several institutional investors have recently added to or reduced their stakes in APYX. Cowen AND Company LLC bought a new position in shares of Apyx Medical during the 4th quarter valued at approximately $1,996,000. Goldman Sachs Group Inc. grew its position in shares of Apyx Medical by 1,148.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 212,439 shares of the company’s stock valued at $1,797,000 after acquiring an additional 195,417 shares during the period. Lighthouse Financial Advisors Inc. bought a new position in shares of Apyx Medical during the 4th quarter valued at approximately $1,465,000. State Street Corp grew its position in shares of Apyx Medical by 34.2% during the 3rd quarter. State Street Corp now owns 557,677 shares of the company’s stock valued at $3,775,000 after acquiring an additional 142,098 shares during the period. Finally, Calamos Advisors LLC bought a new position in shares of Apyx Medical during the 4th quarter valued at approximately $1,164,000. 53.45% of the stock is owned by hedge funds and other institutional investors.

About Apyx Medical (NASDAQ:APYX)

Apyx Medical Corporation, a medical technology company, manufactures and sells medical devices in the cosmetic and surgical markets worldwide. It operates through two segments, Advanced Energy and original equipment manufacturing (OEM). The company develops J-Plasma, a patented plasma-based surgical product for cutting, coagulation, and ablation of soft tissue.

Featured Article: What is the Dow Jones Industrial Average (DJIA)?

Receive News & Ratings for Apyx Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apyx Medical and related companies with MarketBeat.com's FREE daily email newsletter.